Reports Q3 revenue $383.5M, consensus $367.02M. “Phibro delivered a strong third quarter, with net sales increasing 10% to $383.5 million and adjusted EBITDA rising 11% to $60.8 million,” said Jack Bendheim, Chairman, President and Chief Executive Officer of Phibro Animal Health (PAHC) Corporation. “Results were driven by continued strength in our Animal Health business, where sales increased 13%, supported by robust demand across MFAs, nutritional specialties, and vaccines.”
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on PAHC:
- Phibro Animal Health Declares Quarterly Cash Dividend
- PAHC Upcoming Earnings Report: What to Expect?
- Phibro Animal Health Expands Revolving Credit Facility Commitment
- Brazil Antimicrobial Feed Additive Ban Spurs Phibro Response
- Phibro Animal Health discloses new framework on antimicrobials in Brazil